RxDoctor Payments Data

Julie Bostic

Family · Hartford, SDNPI 1700886363

Payments from drug & device makers

$465in general payments, 2019–2025

Across 17 payments — averaging $27.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$191
  • Biohaven Pharmaceutical Holding Company Ltd.$123
  • Sanofi Pasteur Inc.$48
  • Eisai Inc.$24
  • Lilly USA, LLC$20
  • Astellas Pharma US Inc$17
  • plus $42 from 3 others

What the payments were for

  • Food & beverage$45197%
  • Education$143%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$465 in reported general payments places this provider in the 65th percentile of 588 family providers in South Dakota.

See all family providers in South Dakota

Medicare billing

Part B allowed, 2024
$19,543
Medicare patients
131
Services billed
280

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide38$42,113
EliquisApixaban19$24,545
OzempicSemaglutide12$20,892
XareltoRivaroxaban31$19,430
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$14,896
JardianceEmpagliflozin11$14,231
Breo ElliptaFluticasone/Vilanterol17$12,887
Rosuvastatin Calcium158$3,036
Levothyroxine Sodium265$2,451
Atorvastatin Calcium266$2,068
Metoprolol Succinate122$1,907
Estradiol26$1,759
Losartan Potassium194$1,655
Pantoprazole Sodium65$1,601
Carbamazepine19$1,593

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$20$42,11338 claims
Novo NordiskOzempic$14$20,89212 claims
AbbVieSynthroid$191$1,55033 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 588 family providers in South Dakota.

Other family in Hartford

See the full list for South Dakota

Where these figures come from

Is this you, or does something look wrong? →